Logo

AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Share this

AzurRx BioPharma Reports Positive Interim P-II Data of MS1819 + PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Shots:

  • The interim data from 18 patients out of 20 in P-II trial evaluating the safety- tolerability- and efficacy of MS1819 (700/1200/2240 mg- qd- for 15 days/dosing level) + PERT aged 12 yrs or older in CF patients for EPI
  • The 1EP & 2EP of the trial demonstrated improvement in CFA- improvement in stool weight- stool consistency- bowel movements- rate of steatorrhea & increased body weight- reduced the symptoms of EPI- improved QoL with safety profile. The results from all 20 patients enrolled in the trial are expected in Q2' 21
  • The company expects to enrol ~24 CF patients with severe EPI and the study completion is expected in Q1’ 21

  Ref: GLOBE NEWSWIRE| Image: AzurRx BioPharma

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions